Physician profile
Nirupa J Patel
NPI 1851586218
$6,803.34
in general payments reported to CMS, 2019-2025
26 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $314 · 2021: $531 · 2022: $587 · 2023: $915 · 2024: $1,678 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.40 |
| Education | $293.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,584.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,019.49 | 2019-2025 | |
| Glaxosmithkline, LLC. | $954.86 | 2019-2025 | Benlysta |
| Amgen INC. | $806.01 | 2019-2025 | Evenity, Tavneos, Prolia |
| Genzyme Corporation | $297.95 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $293.98 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $273.65 | 2020-2024 | Acthar |
| Ucb, INC. | $257.60 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $191.45 | 2019 | |
| Mallinckrodt Enterprises LLC | $171.94 | 2019 | |
| Aurinia Pharma U.S., INC. | $150.51 | 2022-2025 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $131.79 | 2019-2024 | Eylea Hd |
| Janssen Scientific Affairs, LLC | $123.43 | 2019-2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $83.49 | 2021 | |
| Octapharma USA, INC. | $69.56 | 2023-2024 | Octagam Immune Globulin (Human) |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $66.37 | 2023-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $64.06 | 2024 | Idacio |
| Janssen Biotech, INC. | $62.27 | 2019-2023 | Tremfya |
| Horizon Therapeutics Plc | $49.45 | 2023 | Krystexxa |
| Lilly USA, LLC | $45.93 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $31.16 | 2020 | |
| Eisai INC. | $16.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.46 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $14.92 | 2019 | |
| Shire North American Group INC | $13.75 | 2019 | |
| Qiagen, LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirupa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.